Dow Jones
38.225,66 +322,37 (+0,85%) Nasdaq
15.840,96 +235,48 (+1,51%) Nikkei 225
38.236,07 -37,98 (-0,10%) EUR/USD
1,0738 +0,0010 (+0,10%) Bitcoin EUR
55.446,05 +1.940,00 (+3,63%) CMC Crypto 200
1.282,57 +11,82 (+0,93%)
Bioventus Inc. (BVS)
Dopo ore:
| Chiusura precedente | 3,9900 |
| Aperto | 4,0300 |
| Denaro | 3,9100 x 100 |
| Lettera | 4,0000 x 100 |
| Min-Max giorno | 3,9500 - 4,0300 |
| Intervallo di 52 settimane | 0,9030 - 6,0800 |
| Volume | |
| Media Volume | 142.744 |
| Capitalizzazione | 252,757M |
| Beta (5 anni mensile) | 0,50 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -1,5400 |
| Prossima data utili | 07 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 8,00 |
GlobeNewswireBioventus to Present at the Cantor Global Healthcare Conference
DURHAM, N.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Mark Singleton, senior vice president and chief financial officer, will participate in a fireside chat at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 1:50 p.m. ET. A live audio webcast of the fireside chat will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be availabl
- GlobeNewswire
Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
DURHAM, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Tony Bihl, interim chief executive officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 13, 2023, at 8:50 a.m. ET. A live audio webcast of the fireside chat will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be available for replay o
- GlobeNewswire
Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance
DURHAM, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported financial results for the three and six months ended July 1, 2023. Q2 Financial Summary: Net Sales of $137.1 million, down $3.3 million, or 2.3%, year-over-year as reported (2.3% constant currency*), excluding revenues from divested assets, underlying organic sales decreased $0.5 million, or 0.3% year-over-yearNet Loss from
